Should you thrombolyze all or any stroke patients with baseline national institutes of health stroke scale scores ≤5?

Cerebrovascular Diseases

Volumn 28, Issue 2, 2009, Pages 201-202

  Steffenhagen, Nikolai ^a,c   Hill, Michael D ^a   Poppe, Alexandre Y ^a   Buchan, Alastair M ^b   Coutts, Shelagh B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PATIENT SAFETY; PRIORITY JOURNAL; FIBRINOLYTIC THERAPY; HOSPITALIZATION; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PATIENT SELECTION; REGISTER; RISK; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); ODDS RATIO; PATIENT SELECTION; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 67649440774     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226579     Document Type: Article

References (10)

1. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020. (Pubitemid 32336306)
2. Cocho D, Belvis R, Marti-Fabregas J, Molina-Porcel L, Diaz-Manera J, Aleu A, Pagonabarraga J, Garcia-Bargo D, Mauri A, Marti-Vilalta JL: Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719-720. (Pubitemid 40261906)
3. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM: Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-350. (Pubitemid 38327350)
4. Gladstone D, Hill MD, Black S: TPA for acute stroke: balancing baseline imbalances. CMAJ 2002;166:1652-1653.
5. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH: Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497-2499. (Pubitemid 41566987)
6. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-252. (Pubitemid 41218712)
7. Baumann CR, Baumgartner RW, Gandjour J, von Budingen HC, Siegel AM, Georgiadis D: Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006;37:1332-1333. (Pubitemid 43731885)
8. Hill MD, Buchan AM: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-1312. (Pubitemid 40745072)
9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
10. Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, Vinuela F, Duckwiler G, Jahan R, Fredieu A, Suzuki S, Saver JL: Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006;67:980-984. (Pubitemid 44454588)